Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer

Oncotarget

Volumn 6, Issue 1, 2015, Pages 56-70

  Vendetti, Frank P ^a   Topper, Michael ^a   Huang, Peng ^a   Dobromilskaya, Irina ^a   Easwaran, Hariharan ^a   Wrangle, John ^a   Baylin, Stephen B ^a   Poirier, J T ^b   Rudin, Charles M ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Azacitidine; Chemosensitivity; Entinostat; Epigenetic; Non small cell lung cancer (NSCLC); Priming

Indexed keywords

AZACITIDINE; BORTEZOMIB; CISPLATIN; DOCETAXEL; ENTINOSTAT; GEMCITABINE; IRINOTECAN; NAVELBINE; TANESPIMYCIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CAMPTOTHECIN; HISTONE; PYRIDINE DERIVATIVE;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG SENSITIVITY; EPIGENETICS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CHEMISTRY; DNA METHYLATION; DRUG SCREENING; FEMALE; GENETIC EPIGENESIS; LUNG NEOPLASMS; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BENZAMIDES; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DNA METHYLATION; DRUG EVALUATION, PRECLINICAL; EPIGENESIS, GENETIC; FEMALE; HISTONES; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PYRIDINES;

EID: 84921329779     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2695     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:2895-2899.
3. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:2442-2449.
4. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. NEnglJMed. 2010; 363:1734-1739.
5. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012; 4:120ra117.
6. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:1167-1176.
7. Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A, Moreira AL, Zakowski MF, Travis WD, Sima CS, Kris MG, Ladanyi M. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2013; 26:511-522.
8. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nature reviews Cancer. 2004; 4:707-717.
9. Brzezianska E, Dutkowska A, Antczak A. The significance of epigenetic alterations in lung carcinogenesis. Molecular biology reports. 2013; 40:309-325.
10. Vendetti FP, Rudin CM. Epigenetic therapy in non-smallcell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert opinion on biological therapy. 2013; 13:1273-1285.
11. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced nonsmall cell lung cancer. Cancer discovery. 2011; 1:598-607.
12. Momparler RL, Ayoub J. Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung cancer. 2001; 34:S111-115.
13. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011; 117:1661-1669.
14. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012; 72:2197-2205.
15. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000; 60:6039-6044.
16. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. British journal of cancer. 2006; 94:1087-1092.
17. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. British journal of cancer. 2009; 100:758-763.
18. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141:69-80.
19. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31:4567-4576.
20. Wu J, Hu CP, Gu QH, Li YP, Song M. Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta pharmacologica Sinica. 2010; 31:93-101.
21. Kakihana M, Ohira T, Chan D, Webster RB, Kato H, Drabkin HA, Gemmill RM. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2009; 4:1455-1465.
22. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Molecular cancer research: MCR. 2008; 6:873-883.
23. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, et al. Transient low doses of DNAdemethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer cell. 2012; 21:430-446.
24. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013; 4:2067-2079.
25. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma research. 2008; 18:274-278.
26. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. The Biochemical journal. 2008; 409:581-589.
27. Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2006; 66:6785-6792.
28. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets?. Cancer letters. 2009; 277:8-21.
29. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert opinion on investigational drugs. 2010; 19:1049-1066.
30. Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochimica et biophysica acta. 2010; 1799:717-725.
31. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nature reviews Drug discovery. 2006; 5:769-784.
32. Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y, Channell MM, Liu Y, Casero RA, Jr., Baylin SB, Reed MD, Tellez CS, March TH. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res. 2011; 71:454-462.
33. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009; 69:3364-3373.